(IN BRIEF) Researchers at The Institute of Cancer Research, London, have achieved a breakthrough in the treatment of advanced sarcoma and melanoma through a novel combination of isolated limb perfusion (ILP) and oncolytic virus therapy. In the first clinical trial … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amgen Pharmaceuticals, cancer research, clinical trial, Dr Lucy Bull Foundation, ICR, ILP, immunotherapy, isolated limb perfusion, Journal for ImmunoTherapy of Cancer, London, Mabs Mardulyn Charitable Foundation, melanoma, NIHR Biomedical Research Centre, oncolytic virus, Professor Alan Melcher, Professor Andrew Hayes, Robert McAlpine Foundation, Royal Marsden Melanoma and Sarcoma Research Fund, sarcoma, Sarcoma UK, T-VEC, talimogene laherparepvec, The Institute of Cancer Research, The Institute of Cancer Research pioneers new dual treatment combining virus therapy and isolated limb perfusion to enhance immune response in advanced cancer, The Royal Marsden NHS Foundation Trust, tumour immunity, United Kingdom, virotherapy
(IN BRIEF) The Institute of Cancer Research, London, has published two major studies demonstrating how pairing a cancer-killing reovirus with targeted therapies such as talazoparib and palbociclib can greatly strengthen immune activity and tumour destruction. By disrupting cancer cell defences … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Technology, United Kingdom
Tagged Cancer Research UK, immune activation, immune checkpoint inhibitors, Joan Kyula-Currie, Kevin Harrington, London, Nature Communications, oncolytic virus, Oncolytics Biotech, Palbociclib, PARP-1, personalised cancer therapies, reovirus, RIG-I, Royal Marsden, talazoparib, The Institute of Cancer Research, tumour stress response, Victoria Roulstone, virotherapy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?